Lapatinib, a dual EGFR and HER2 inhibitor, are clinically effective against HER2-amplified breast cancer by blocking HER2 phosphorylation, resulting in inhibition of downstream PI3K/AKT and MAPK pathways [36]. This evidence concerns the gene PIK3CG and breast cancer.